Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
2,767
Views
4
CrossRef citations to date
0
Altmetric
Research Papers

Identification of novel non-toxic and anti-angiogenic α-fluorinated chalcones as potent colchicine binding site inhibitors

Moran Suna Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China;b Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmaceutical Sciences, Ministry of Education, Zhengzhou University, Zhengzhou, China;View further author information
,
Minghua Yuanb Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmaceutical Sciences, Ministry of Education, Zhengzhou University, Zhengzhou, China;View further author information
,
Yingying Kangb Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmaceutical Sciences, Ministry of Education, Zhengzhou University, Zhengzhou, China;View further author information
,
Jinling Qinb Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmaceutical Sciences, Ministry of Education, Zhengzhou University, Zhengzhou, China;View further author information
,
Yixin Zhangb Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmaceutical Sciences, Ministry of Education, Zhengzhou University, Zhengzhou, China;View further author information
,
Yongtao Duana Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaView further author information
,
Longfei Wanga Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, ChinaCorrespondence[email protected]
View further author information
&
Yongfang Yaoa Henan Provincial Key Laboratory of Children's Genetics and Metabolic Diseases, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou University, Zhengzhou, China;b Key Laboratory of Advanced Drug Preparation Technologies, School of Pharmaceutical Sciences, Ministry of Education, Zhengzhou University, Zhengzhou, China;;c State Key Laboratory of Esophageal Cancer Prevention & Treatment, School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 339-354 | Received 12 Sep 2021, Accepted 30 Nov 2021, Published online: 03 Jan 2022

References

  • Kaasa S, Loge JH, Aapro M, et al. Integration of oncology and palliative care: a lancet oncology commission. Lancet Oncol 2018;19:E588–653.
  • Holohan C, Schaeybroeck SV, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013;13:714–26.
  • (a) Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423–35. (b) Mckeage MJ, Baguley BC. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010;116:1859–71.
  • Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res 2009;15:2594–601.
  • Liu ZP, Liu YN, Ji YT. Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments. Curr Med Chem 2015;22:1348–60.
  • Porcu E, Bortolozzi R, Basso G, Viola G. Recent advances in vascular disrupting agents in cancer therapy. Future Med Chem 2014;6:1485–98.
  • Kanthou C, Tozer GM. The tumor vascular targeting agent Combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060–9.
  • Ducki S, Rennison D, Woo M, et al. Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: synthesis and biological evaluation of antivascular activity. Bioorg Med Chem 2009;17:7698–710.
  • Zweifel M, Jayson GC, Reed N, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:2036–41.
  • Zhuang C, Zhang W, Sheng C, et al. Chalcone: a privileged structure in medicinal chemistry. Chem Rev 2017;117:7762–810.
  • Yan J, Chen J, Zhang S, et al. Synthesis, evaluation, and mechanism study of novel indole-chalcone derivatives exerting effective antitumor activity through microtubule destabilization in vitro and in vivo. J Med Chem 2016;59:5264–83.
  • Canela MD, Noppen S, Bueno O, et al. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091. Oncotarget 2017;8:14325–42.
  • Saito Y, Mizokami A, Izumi K, et al. α-Trifluoromethyl chalcones as potent anticancer agents for androgen receptor-independent prostate cancer. Molecules 2021; 26:2812.
  • Liu YZ, Wang XL, Wang XY, et al. De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach. J Mol Model 2016;22:1–8.
  • (a) Sun MR, Zhang YX, Qin JL, et al. Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: potent inhibitors of angiogenesis and tubulin polymerization. Bioorg Chem 2021;113:104988. (b) Wang YG, Sun MR, Wang YY et al. Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency. Eur J Med Chem 2021;225:113790.
  • Díaz JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747–55.
  • Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted antimitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107–17.
  • Afshari CA, Barrett JC. Cell cycle controls: potential targets for chemical carcinogens? Environ Health Persp 1993;101:9–14.
  • Jackman M, Lindon C, Nigg EA, Pines J. Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 2003;5:143–8.
  • Hensley P, Mishra M, Kyprianou N. Targeting caspases in cancer therapeutics. Biol Chem 2013;394:831–43.
  • Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81–6.
  • Shi YW, Yuan W, Wang X, et al. Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish. Sci Rep-UK 2016;6:30189.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.